JP7716988B2 - Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤 - Google Patents

Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤

Info

Publication number
JP7716988B2
JP7716988B2 JP2021564994A JP2021564994A JP7716988B2 JP 7716988 B2 JP7716988 B2 JP 7716988B2 JP 2021564994 A JP2021564994 A JP 2021564994A JP 2021564994 A JP2021564994 A JP 2021564994A JP 7716988 B2 JP7716988 B2 JP 7716988B2
Authority
JP
Japan
Prior art keywords
composition
ecd
fusion molecule
concentration
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531387A (ja
JP2022531387A5 (https=
Inventor
ヨン チュアン，
Original Assignee
ファイヴ プライム セラピューティクス インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイヴ プライム セラピューティクス インク filed Critical ファイヴ プライム セラピューティクス インク
Publication of JP2022531387A publication Critical patent/JP2022531387A/ja
Publication of JP2022531387A5 publication Critical patent/JP2022531387A5/ja
Application granted granted Critical
Publication of JP7716988B2 publication Critical patent/JP7716988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021564994A 2019-05-03 2020-05-01 Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤 Active JP7716988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962842722P 2019-05-03 2019-05-03
US62/842,722 2019-05-03
PCT/US2020/030946 WO2020227062A1 (en) 2019-05-03 2020-05-01 Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Publications (3)

Publication Number Publication Date
JP2022531387A JP2022531387A (ja) 2022-07-06
JP2022531387A5 JP2022531387A5 (https=) 2023-05-12
JP7716988B2 true JP7716988B2 (ja) 2025-08-01

Family

ID=70847527

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564994A Active JP7716988B2 (ja) 2019-05-03 2020-05-01 Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤

Country Status (9)

Country Link
US (1) US20220227834A1 (https=)
EP (1) EP3963079A1 (https=)
JP (1) JP7716988B2 (https=)
AR (1) AR118853A1 (https=)
AU (1) AU2020270395A1 (https=)
CA (1) CA3136831A1 (https=)
MX (1) MX2021013272A (https=)
TW (1) TW202108126A (https=)
WO (1) WO2020227062A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
WO2026062544A1 (en) * 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535204A (ja) 2015-11-02 2018-11-29 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018535204A (ja) 2015-11-02 2018-11-29 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用

Also Published As

Publication number Publication date
WO2020227062A1 (en) 2020-11-12
AU2020270395A1 (en) 2021-12-23
EP3963079A1 (en) 2022-03-09
JP2022531387A (ja) 2022-07-06
CA3136831A1 (en) 2020-11-12
AR118853A1 (es) 2021-11-03
MX2021013272A (es) 2021-11-17
US20220227834A1 (en) 2022-07-21
TW202108126A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
JP7653465B2 (ja) 単独およびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JP7716988B2 (ja) Ｃｄ８０細胞外ドメイン－ｆｃ融合タンパク質を含む医薬製剤
ES2813580T3 (es) Composiciones que comprenden una combinación de ipilimumab y nivolumab
JP2022116099A (ja) インターロイキン－２１ムテイン及び治療方法
TW202126683A (zh) Ｔ細胞調節多肽及其使用方法
AU2018229724B2 (en) Aqueous anti-PD-L1 antibody formulation
JP2024512470A (ja) Ｔ細胞調節ポリペプチド及びその使用方法
CN112771067A (zh) 包含基于SIRPα的嵌合蛋白的组合疗法
KR20200089282A (ko) 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
TW202130367A (zh) 結合ｐｄ－１和ｐｄ－ｌ１的雙特異性抗體的製劑及其用途
TWI782397B (zh) 重組全人源抗ｔｉｇｉｔ單株抗體製劑及其製備方法和用途
TW202311293A (zh) 免疫療法之組合及其用途
JP2025142195A (ja) 抗ｐｄ－１／ｈｅｒ２二重特異性抗体を含む製剤及びその調製方法と使用
WO2022111612A1 (zh) 包含抗tigit/pd-1双特异性抗体的制剂及其制备方法和用途
KR20210131312A (ko) 인간 cd137에 결합하는 항체의 제제 및 이의 용도
KR102604984B1 (ko) Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
JP2023538902A (ja) 操作されたリガンドを使用する材料及び方法
IL305265A (en) Preparations of DR5-binding polypeptides
US20230036928A1 (en) Anti-tgf-beta antibody formulations and their use
US20260083857A1 (en) Anti-pd-1 antibody-attenuated il-2 immunoconjugate formulations
WO2023186079A9 (zh) Cd80蛋白变体及cd80融合蛋白
WO2024193670A9 (zh) 抗pd-1与突变il-2免疫缀合物制剂
EA052873B1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250722

R150 Certificate of patent or registration of utility model

Ref document number: 7716988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150